Fermion’s FZ008-145 Receives IND Approval by China’s NMPA for Pain Relief
Shots:
- The company’s IND application for FZ008-145 has been approved by China’s NMPA for 5 acute pain and 1 chronic pain proof-of-concept (POC) trials
- Joincare Pharmaceutical holds exclusive rights to the company's FZ008-145 in the Greater China region while Fermion has the rights outside of Greater China
- FZ008-145 is a non-addictive pain relief drug that targets Nav1.8 aimed at providing powerful, non-addictive pain relief advantages
Ref: PRNewswire | Image: Fermion
Related News:- Abbott to Launch NeuroSphere myPath App to Record Pain Relief in Chronic Pain Patients
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Shivani is a content writer at PharmaShots. She has a keen interest in recent innovations in the life sciences industry. She covers news related to Product approvals, clinical trial results, and updates. She can be contacted at connect@pharmashots.com.
